四重療法

Ask MedXY AI

Latest news

Tag

Cardiologycost offsetguideline-directed medical therapy

Economic Impact and Clinical Benefits of Quadruple Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Comprehensive Review

By MedXY|Jul 3, 2026

This review synthesizes evidence demonstrating that implementing full quadruple GDMT (ARNI, β-blockers, MRAs, SGLT2i) in HFrEF reduces hospitalization risks and healthcare costs, often yielding net savings despite medication expenses.

CardiologyGDMThealth equity

Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical Practice

By MedXY|Apr 5, 2026

A large retrospective study of 52,850 veterans reveals that just 21.2% achieve guideline-directed quadruple therapy for HFrEF, with a median time of 197 days. Socioeconomic barriers, including prescription copays, emerge as critical modifia

CardiologyGDMTHFrEF

Residual Clinical Risk and Economic Burden in HFrEF: Insights from the Quadruple Medical Therapy Era

By MedXY|Mar 15, 2026

This review analyzes the real-world one-year outcomes and healthcare costs for HFrEF patients on quadruple therapy, revealing significant residual risk despite optimized pharmacologic management.